CH603608A5 - - Google Patents

Info

Publication number
CH603608A5
CH603608A5 CH696276A CH696276A CH603608A5 CH 603608 A5 CH603608 A5 CH 603608A5 CH 696276 A CH696276 A CH 696276A CH 696276 A CH696276 A CH 696276A CH 603608 A5 CH603608 A5 CH 603608A5
Authority
CH
Switzerland
Application number
CH696276A
Inventor
Guenther Dr Heubach
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2524959A external-priority patent/DE2524959C2/de
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of CH603608A5 publication Critical patent/CH603608A5/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66Nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CH696276A 1975-06-05 1976-06-02 CH603608A5 (US06397114-20020528-M00001.png)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2524959A DE2524959C2 (de) 1975-06-05 1975-06-05 5-Methyl-isoxazol-4-carbonsäureanilide, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Mittel

Publications (1)

Publication Number Publication Date
CH603608A5 true CH603608A5 (US06397114-20020528-M00001.png) 1978-08-31

Family

ID=5948292

Family Applications (1)

Application Number Title Priority Date Filing Date
CH696276A CH603608A5 (US06397114-20020528-M00001.png) 1975-06-05 1976-06-02

Country Status (15)

Country Link
US (1) US4087535A (US06397114-20020528-M00001.png)
JP (1) JPS5938230B2 (US06397114-20020528-M00001.png)
AT (1) AT349007B (US06397114-20020528-M00001.png)
BE (1) BE842689A (US06397114-20020528-M00001.png)
CA (1) CA1076584A (US06397114-20020528-M00001.png)
CH (1) CH603608A5 (US06397114-20020528-M00001.png)
DK (1) DK151013C (US06397114-20020528-M00001.png)
ES (1) ES448386A1 (US06397114-20020528-M00001.png)
FR (1) FR2313052A1 (US06397114-20020528-M00001.png)
GB (1) GB1547452A (US06397114-20020528-M00001.png)
IE (1) IE43136B1 (US06397114-20020528-M00001.png)
IT (1) IT1063592B (US06397114-20020528-M00001.png)
LU (1) LU75077A1 (US06397114-20020528-M00001.png)
MX (1) MX3144E (US06397114-20020528-M00001.png)
NL (1) NL178596C (US06397114-20020528-M00001.png)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2654797A1 (de) * 1976-12-03 1978-06-08 Hoechst Ag Verfahren zur herstellung von isoxazolderivaten
JPS54102196U (US06397114-20020528-M00001.png) * 1977-12-28 1979-07-18
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
ATE14724T1 (de) * 1979-06-11 1985-08-15 Ciba Geigy Ag Alphacarbamoyl-pyrrolpropionitrile, verfahren zu ihrer herstellung, sowie pharmazeutische praeparate die diese verbindungen enthalten.
DE2940189A1 (de) * 1979-10-04 1981-04-16 Basf Ag, 6700 Ludwigshafen Isoxazolylcarbonsaeureanilide, verfahren zu ihrer herstellung und ihre verwendung als fungizide
FR2538806B1 (fr) * 1982-12-30 1986-02-21 Bago Sa Labor Composes phenyl-3 methyl isoxazole-5 carboxy-4 anilides substitues, actifs therapeutiquement contre l'inflammation et la douleur
JPS6398092A (ja) * 1986-10-14 1988-04-28 富士電機株式会社 金券用カ−ド残金精算装置
US4935434A (en) * 1988-01-26 1990-06-19 Bristol-Myers Company Antiarthritic isoxazole-4-carboxamides
DD297328A5 (de) 1989-08-18 1992-01-09 �������@���������k���Kk�� 5-methyl-isoxalol-4-carbonsaeureanilide und 2 hydroxyethyliden-cyanoessigsaeureanilide zur behandlung von augenerkrankungen
US5583150A (en) * 1989-08-18 1996-12-10 Alcon Laboratories, Inc. 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
US5001124A (en) * 1990-02-02 1991-03-19 Syntex (U.S.A.) Inc. 4-isoxazolecarboxamide derivatives
US5108999A (en) * 1990-02-02 1992-04-28 Syntex (U.S.A.) Inc. 4-isoxazolecarboxamide derivatives
US5494911A (en) * 1990-05-18 1996-02-27 Hoechst Aktiengesellschaft Isoxazole-4-carboxamides and hydroxyalkylidenecyanoacetamides, pharmaceuticals containing these compounds and their use
DE4127737A1 (de) 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
US6133301A (en) * 1991-08-22 2000-10-17 Aventis Pharma Deutschland Gmbh Pharmaceuticals for the treatment of rejection reactions in organ transplantations
GB9320299D0 (en) * 1993-10-01 1993-11-17 Roussel Lab Ltd Isoxazole derivatives
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US6335356B1 (en) 1994-01-07 2002-01-01 Sugen, Inc. Method of treating a patient by parenteral administration of a lipophilic compound
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US5624946A (en) * 1994-07-05 1997-04-29 Williams; James Use of leflunomide to control and reverse chronic allograft rejection
US5721277A (en) * 1995-04-21 1998-02-24 Sugen, Inc. Compounds and methods for inhibiting hyper-proliferative cell growth
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
ES2150808T3 (es) * 1997-08-08 2000-12-01 Aventis Pharma Gmbh Forma cristalina de (4-trifluorometil)-anilida de acido 5-metilisoxazol-4-carboxilico.
US7691890B2 (en) 1998-03-11 2010-04-06 James W. Williams Anti-viral uses of leflunomide products
US20050255071A1 (en) * 1998-12-10 2005-11-17 Aventis Pharma Deutschland Gmbh Preparation having improved therapeutic breadth comprising nucleotide synthesis inhibitors
GB0123571D0 (en) * 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
CA2443285C (en) 2001-04-05 2007-08-21 Aventis Pharmaceuticals Inc. Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
US8008501B2 (en) * 2003-09-12 2011-08-30 Rigel Pharmaceuticals, Inc. Quinoline compounds and their uses
WO2006004865A1 (en) * 2004-06-29 2006-01-12 Rigel Pharmaceuticals, Inc. 2-substituted quinoline compounds and their uses as inhibitors of the ige receptor signaling cascade
US20060024376A1 (en) * 2004-07-30 2006-02-02 The University Of Chicago Methods and compositions for reducing toxicity associated with leflunomide treatment
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK54063C (da) * 1935-02-22 1937-12-27 Hoffmann La Roche Fremgangsmaade til Fremstilling af dialkylsubstituerede Amider af Isoksazolkarbonsyrer.
DE634286C (de) * 1935-02-23 1936-08-26 Hoffmann La Roche & Co Akt Ges Verfahren zur Herstellung dialkylsubstituierter Amide von Isoxazolcarbonsaeuren
US2126329A (en) * 1936-03-20 1938-08-09 Hoffmann La Roche Amide derivatives of isoxazole carboxylic acids
DE673111C (de) * 1938-01-18 1939-03-16 Hoffmann La Roche & Co Akt Ges Verfahren zur Darstellung amidartiger Abkoemmlinge von Homologen der Isoxazolcarbonsaeuren
US2288863A (en) * 1940-02-27 1942-07-07 Hoffmann La Roche Process for the manufacture of substituted amides of 3,5-dimethylisoxazole-4-carboxylic acid
DK58903C (da) * 1940-02-27 1941-08-04 Hoffmann La Roche Fremgangsmaade til Fremstilling af substituerede Amider af 3,5-Dimetyl-isoksazol-karbonsyre-(4).

Also Published As

Publication number Publication date
DK248376A (da) 1976-12-06
BE842689A (fr) 1976-12-08
IE43136B1 (en) 1980-12-31
GB1547452A (en) 1979-06-20
US4087535A (en) 1978-05-02
IT1063592B (it) 1985-02-11
CA1076584A (en) 1980-04-29
FR2313052B1 (US06397114-20020528-M00001.png) 1979-09-28
DK151013B (da) 1987-10-12
JPS527960A (en) 1977-01-21
ATA413776A (de) 1978-08-15
NL178596C (nl) 1986-04-16
AT349007B (de) 1979-03-12
NL7605841A (nl) 1976-12-07
IE43136L (en) 1976-12-05
FR2313052A1 (fr) 1976-12-31
ES448386A1 (es) 1978-04-16
JPS5938230B2 (ja) 1984-09-14
MX3144E (es) 1980-05-09
DK151013C (da) 1988-03-07
LU75077A1 (US06397114-20020528-M00001.png) 1977-03-09

Similar Documents

Publication Publication Date Title
FR2313052B1 (US06397114-20020528-M00001.png)
FI761234A (US06397114-20020528-M00001.png)
JPS5718616B2 (US06397114-20020528-M00001.png)
FR2333190B1 (US06397114-20020528-M00001.png)
JPS5443972B2 (US06397114-20020528-M00001.png)
JPS51136763U (US06397114-20020528-M00001.png)
JPS5263147U (US06397114-20020528-M00001.png)
JPS5262230U (US06397114-20020528-M00001.png)
JPS5431225Y2 (US06397114-20020528-M00001.png)
JPS5426870Y2 (US06397114-20020528-M00001.png)
JPS51120384U (US06397114-20020528-M00001.png)
JPS5242606U (US06397114-20020528-M00001.png)
JPS51119942U (US06397114-20020528-M00001.png)
JPS51120435U (US06397114-20020528-M00001.png)
JPS51129142U (US06397114-20020528-M00001.png)
JPS51158441U (US06397114-20020528-M00001.png)
JPS5232698U (US06397114-20020528-M00001.png)
JPS5275863U (US06397114-20020528-M00001.png)
JPS5289588U (US06397114-20020528-M00001.png)
JPS5236458U (US06397114-20020528-M00001.png)
JPS5288283U (US06397114-20020528-M00001.png)
BG22316A1 (US06397114-20020528-M00001.png)
CH594743A5 (US06397114-20020528-M00001.png)
CH581556A5 (US06397114-20020528-M00001.png)
BG22264A1 (US06397114-20020528-M00001.png)

Legal Events

Date Code Title Description
PL Patent ceased